BridgeMD
New treatment option for Pancreatic Cancer
Official title A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
ClinicalTrials.gov ID: NCT06151262
What this study is testing
What is Trilaciclib+mFOLFIRINOX?
Trilaciclib+mFOLFIRINOX is an investigational medicine, being studied as a potential treatment for pancreatic cancer.
Also referred to as G1T28, CDK 4/6 inhibitor.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To observe the incidence of chemotherapy-induced myelosuppression and the safety of Trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line treatment.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age 18-75 years
- ECOG score 0 or 1
- Expected survival≥12 weeks
- Patients with histologically or cytologically confirmed pancreatic cancer
- Have not received any antineoplastic therapy prior to treatment
You likely can't join if
- Had received systemic antineoplastic therapy
- Pregnant and lactating women. Women of childbearing age had to test a negative pregnancy test within 7 days before enrollment
- Substance abuse, clinical or psychological or social factors that may interfere with informed consent or the conduct of the study
See the full eligibility criteria
- Age 18-75 years
- ECOG score 0 or 1
- Expected survival≥12 weeks
- Patients with histologically or cytologically confirmed pancreatic cancer
- Have not received any antineoplastic therapy prior to treatment
- Major organ functions within 7 days prior to treatment shall meet the following criteria: a. Neutrophil count ≥1.5×109 /L； b. Hemoglobin ≥10g/dL； c. Platelet count ≥100×109 /L
- Biochemical examination shall meet the following standards: a、Total bilirubin(TBIL)≤1.5times the upper limit of normal value(ULN); b、ALT and AST≤1.5×ULN ; c、creatinine clearance(CCr)≥60ml/min
- Patients of reproductive age(including female and male patients'female companions)must use effective birth control measures
- people voluntarily joined the study and signed an informed consent form(ICF)
- It is expected that the patient has good compliance and can follow up the how well it works and adverse reactions according to the protocol requirements
- Had received systemic antineoplastic therapy
- Pregnant and lactating women. Women of childbearing age had to test a negative pregnancy test within 7 days before enrollment
- Substance abuse, clinical or psychological or social factors that may interfere with informed consent or the conduct of the study
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.